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Abstract
Neuroleptic-induced tardive dyskinesia has been linked to impaired iron homeostasis in the central nervous system
attributed to increased iron levels. A chlorpromazine stimulatory effect upon iron uptake from 55Fe-citrate and 55Fe-
transferrin by cortical synaptosome preparations of rats was recently demonstrated. The present work extends this study to
other neuroleptic drugs such as thioridazine, haloperidol, clozapine and fluphenazine. Like chlorpromazine, thioridazine
showed a stimulatory effect upon iron uptake from both iron donors whereas fluphenazine highly increased uptake from
55Fe-citrate but not from 55Fe-transferrin. Haloperidol and clozapine had no effect. Stimulation of iron uptake by
neuroleptics is probably related to their property of calmodulin antagonism, since calmidazolium also stimulated
synaptosomal iron uptake from both donors. Calmidazolium-stimulated uptake from 55Fe-citrate was approx. 5-fold when
compared to control samples while uptake from 55Fe-transferrin was 250% higher. The results are in agreement with the iron
uptake magnitude observed with the different drugs for the two iron donors used and the reported Ki values of neuroleptic
drugs for calmodulin antagonism evaluated by the inhibition of 3P,5P-monophosphate phosphodiesterase activity. Moreover,
vanadate, an inhibitor of protein phosphorylation and KCl-promoted membrane depolarization, greatly inhibited iron
uptake from 55Fe-citrate by both chlorpromazine-treated and untreated synaptosome preparations. z 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
For the majority of cell types, the mechanism of
cellular iron uptake is receptor-mediated and the iron
delivered by transferrin. However, alternative mech-
anisms have been described such as non-receptor-
mediated uptake from transferrin by hepatocytes
[1], iron uptake from di¡erent iron donors like the
complex iron-nitrilotriacetate in K562 cells [2], and
ATP-dependent uptake from iron-citrate by the
hepatocyte nucleus [3]. Moreover, iron-binding
proteins implicated in iron uptake by cells other
than transferrin or ferritin have been identi¢ed,
such as mobilferrin and integrin in K562 cells [4]
and in duodenal mucosa [5,6]. Inman et al. [7] also
reported the involvement of ferrireductase activity
during iron transport by K562 cells independent of
transferrin. Recently, we demonstrated iron uptake
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from 55Fe-citrate by a synaptosome preparation of
rat cerebral cortex [7]. The iron uptake by synapto-
somes from both 55Fe-citrate and 55Fe-transferrin
was found to be intensi¢ed by the neuroleptic chlor-
promazine, a phenothiazinic drug. Relevant in this
respect are clinical and experimental literature data
pointing out that tardive dyskinesia, the most severe
side-e¡ect of the majority of neuroleptic drugs,
would be related to iron deposition in some brain
areas after prolonged administration of neuroleptics
[9^11].
In the present work we study the e¡ect of structur-
ally non-related neuroleptic drugs on the iron uptake
by cortical synaptosomes from both iron donor com-
plexes, citrate and transferrin, in an attempt to elu-
cidate the biochemical mechanism underlying neuro-
leptic-stimulated iron uptake.
2. Materials and methods
2.1. Materials
55FeCl3 (4.51 mCi/mmol) was purchased from
Amersham. Apotransferrin, chlorpromazine (CPZ),
FURA2-AM, haloperidol (HAL), imipramine
(IMI), nitrilotriacetic acid (NTA), 2,5-diphenyloxa-
zole (PPO), 1,4-bis[4-methyl-5-phenyl-2-oxazolyl]
benzene (POPOP) and vanadate were obtained
from Sigma. Filters GF/B were from Whatman. Thi-
oridazine (TRZ) and clozapine (CLO) were kindly
donated by Sandoz and £uphenazine (FPZ) by Cris-
ta¤lia. All other reagents were of analytical grade.
Stock solutions were prepared with Millipore MilliQ
deionized water.
2.2. Synaptosome preparation
Synaptosomes were prepared from cerebral cortex
according to Cotman and Matthews [12]. Two-
month-old rats (180^220 g) were sacri¢ced by cervi-
cal dislocation, the brain removed and the tissue im-
mediately dissected at about 4‡C for synaptosome
preparation. Protein concentration was determined
by the method of Lowry. The time window for using
synaptosomes viable for iron uptake, stored at 4‡C,
was found to be 2 days.
2.3. 55Fe-Citrate and 55Fe-transferrin assay
This assay was the same as described by Demasi
and Bechara [8] with some modi¢cations. Synapto-
somes were diluted to a ¢nal concentration of
0.5 mg/ml in normally aerated 10 mM HEPES bu¡-
er, pH 7.4, containing: 124 mM NaCl, 5 mM KCl,
1.24 mM KH2PO4, 1.3 mM MgCl2, 1.0 mM CaCl2
and 10 mM glucose. Synaptosome samples were in-
cubated in this medium at 37‡C for 15 min prior to
the addition of 55Fe-citrate or 55Fe-transferrin. 55Fe-
Species concentrations, drug additions and incuba-
tion times are speci¢ed in the legends of the ¢gures.
The incubation was stopped by centrifugation of the
samples in an Eppendorf microcentrifuge at maxi-
mum speed for 2 min. This procedure was repeated
twice. Finally, the samples were resuspended in 1 ml
of bu¡er and rapidly ¢ltered through Whatman GF/
B ¢lters in a Millipore multifold system apparatus.
The ¢lters were washed twice with 3 ml of bu¡er,
dried at 45‡C, transferred to the liquid scintillation
(0.5% PPO plus 0.01% POPOP dissolved in toluene)
and counted in a Tricarb Packard liquid scintillation
analyzer. The molar concentration of radiolabeled
iron was estimated by direct counting of 55Fe-spe-
cies-containing aliquots. Because this procedure re-
fers to total synaptosome-associated 55Fe-species
(uptake plus membrane binding), sonicated synapto-
somal samples subsequently treated with the iron
donor were prepared in order to evaluate the extent
of actual 55Fe-citrate uptake, distinguishable from
membrane 55Fe-citrate binding [8]. After incubation,
the samples were washed three times by centrifuga-
tion to eliminate soluble external iron. Iron uptake
levels were found to represent approx. 40% of the
total synaptosome-associated iron. Control assays
in the absence of neuroleptics allow the conclusion
that there is actual neuroleptic-mediated synaptoso-
mal iron internalization from 55Fe-citrate and 55Fe-
transferrin as donors. Non-speci¢c counting (55Fe-
species non-synaptosome-associated) was determined
by incubating 55Fe-species-containing aliquots in the
absence of tissue. This blank contributes less than 5%
of the total counts. Iron uptake was determined as
the di¡erence between counts in the presence and
absence of synaptosomes. Results are expressed as
iron equivalents per mg of protein per incubation
time.
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55Fe-Citrate was obtained by mixing 55FeCl3 ali-
quots with sodium citrate immediately before assay
(molar ratio 55FeCl3 :citrate was 1:2). 55Fe-Loaded
transferrin was obtained according to Konopka
and Romslo [13]. Apotransferrin was dissolved in
10 mM HEPES bu¡er, pH 7.4 containing 10 mM
NaHCO3 and 0.1 mM NaClO4. 55FeCl3 was dis-
solved in NTA (120% 55FeCl3 to NTA) and the com-
plex 55Fe-NTA transferred to the apotransferrin-con-
taining solution. The ¢nal solution was dialyzed
against 20 mM NaHCO3 overnight. The diferric-
transferrin absorbance was read at 466 nm and 280
nm and identi¢ed by the ratio A466/A280 (0.045, ac-
cording to Nilsen [14]).
Scheme 1. Chemical structures of neuroleptic drugs.
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3. Results
3.1. E¡ect of neuroleptic drugs on iron uptake from
55Fe-citrate and 55Fe-transferrin by synaptosome
preparations
Iron uptake by cortical synaptosome preparations
from 55Fe-citrate and 55Fe-transferrin was assayed in
the presence of chlorpromazine (CPZ), £uphenazine
(FPZ), thioridazine (TRZ), clozapine (CLO), halo-
peridol (HAL) and imipramine (IMI) at increasing
concentrations (Scheme 1). As depicted in Fig. 1,
FPZ, CPZ, TRZ and IMI stimulated iron uptake
when 55Fe-citrate was used as iron donor. Previously,
synaptosomal iron uptake from 55Fe-citrate and
55Fe-transferrin had been shown to reach saturation
upon increase of incubation time and CPZ concen-
tration [8]. The present study employed the same
experimental conditions and the processes were fol-
lowed for 20 min at neuroleptic concentration below
500 WM, when the steady state saturation condition
is attained. Fluphenazine exhibited a higher stimula-
tory e¡ect upon iron uptake (approx. 4-fold at 250
WM) when compared to the control sample. Imi-
pramine had a lower e¡ect when compared to the
phenothiazine drugs (50% of increased iron uptake)
whereas haloperidol and clozapine were not e¡ective.
Imipramine was assayed in order to verify whether
structurally related drugs, e.g. tricyclic compounds
such as phenothiazines and tricyclic antidepressants,
could in£uence iron uptake due to iron interactions
with the membrane surface. Noteworthy, however, is
that IMI and phenothiazine drugs, besides being
structurally related, share other properties like cal-
modulin antagonism as discussed below.
With 55Fe-transferrin as donor, 250 WM TRZ
stimulated iron uptake by approx. 3-fold (Fig. 2).
Except for CPZ [8], the other drugs tested had no
e¡ect.
3.2. Calmodulin antagonism versus iron uptake
As long attested [15,16], many neuroleptic drugs
share the property of antagonizing calmodulin with
di¡erent inhibition constants for 3P,5P-monophos-
phate phosphodiesterase activity (Ki, see Table 1).
In order to verify whether stimulation of iron uptake
was due to this property, synaptosome preparations
were challenged with 10 WM calmidazolium (CaM), a
potent calmodulin inhibitor, and the iron uptake was
assayed with both 55Fe-citrate and 55Fe-transferrin
(Figs. 1 and 2). As depicted in Figs. 1 and 2, CaM
greatly increased iron uptake from both donors, es-
pecially when the donor utilized was 55Fe-citrate (5-
fold against 250% in the case of 55Fe-transferrin as
donor). These data suggest that iron uptake from
Fig. 1. Synaptosomal iron uptake from 55Fe-citrate in the pres-
ence of neuroleptic drugs. Synaptosome preparations (0.5 mg/
ml) were resuspended in 10 mM HEPES bu¡er, pH 7.4, con-
taining 124 mM NaCl, 5 mM KCl, 1.24 mM KH2PO4, 1.3 mM
MgCl2, 1 mM CaCl2 and 10 mM glucose, and incubated at
37‡C for 20 min, in the presence of indicated neuroleptic con-
centrations and 50 WM 55Fe-citrate. After incubation samples
were washed twice by centrifugation and iron uptake deter-
mined as described in Section 2. CaM, 10 WM calmidazolium.
Control, drug-free samples. Results represent data of three to
four independent experiments which agreed within 10%.
Table 1
Comparative values of the Ki for phosphodiesterase of antical-
modulin drugs and iron uptake stimulation
Drug Ki (WM) 55Fe-citrate 55Fe-Tf
Thioridazine 18a 2.3 3.0
Chlorpromazine 42a 1.7 2.0
Haloperidol 60a 0 0
Clozapine 80a 0 0
Imipramine 125b 0.5 0
Fluphenazine ^ 3.7 0
Calmidazolium ^ 5.0 2.5
Ratios of iron uptake from 55Fe-citrate and 55Fe-Tf observed in
the presence and absence of 250 WM of listed drugs (shown in
Figs. 1 and 2).
aLevin and Weiss [15].
bLevin and Weiss [16].
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55Fe-citrate is much more sensitive to calmodulin in-
hibition than that from 55Fe-transferrin. When one
compares the Ki values for cyclic nucleotide phos-
phodiesterase calmodulin-dependent activity of the
di¡erent drugs with their stimulatory e¡ect at a con-
centration of 250 WM (Table 1), it can be seen that
the observed e¡ects parallel the drug capacity to in-
hibiting calmodulin. Fluphenazine is an irreversible
antagonist of calmodulin and surprisingly did not
have any e¡ect upon iron uptake from 55Fe-Tf. On
the other hand, the calmidazolium e¡ect upon iron
uptake from citrate was 2-fold higher than that ob-
served with 55Fe-Tf as donor.
In an attempt to better understand the e¡ect of
calmodulin on iron uptake, drugs that interfere in
the intracellular calmodulin-dependent cellular sig-
naling were assayed. Among them, forskolin and iso-
prenaline were used to increase intrasynaptosomal
AMPc which can be a possibility of calmodulin-de-
pendent phosphodiesterase inhibition; staurosporine,
a potent inhibitor of the calmodulin-dependent pro-
tein kinases A, C and G; vanadate, an inhibitor of
protein phosphorylation; and okadaic acid, an inhib-
itor of protein phosphatase 2A. As depicted in Table
2, 100 WM vanadate inhibited iron uptake of control
samples by only 25%. Incubation in the presence of
10 WM forskolin, 10 WM isoprenaline or 1 WM oka-
daic acid had no e¡ect upon iron uptake and 5 WM
staurosporine had little inhibitory e¡ect on iron up-
take from control or CPZ-incubated synaptosome
preparations (18%).
The vanadate inhibitory e¡ect upon iron uptake
from 55Fe-citrate was concentration-dependent in
both the presence and absence of 250 WM CPZ
(Fig. 3). Two millimolar vanadate inhibited 55Fe up-
take in control and CPZ-incubated samples by 46%
and 25%, respectively.
3.3. E¡ect of Ca2+ availability on iron uptake
As the intracellular activity of calmodulin is
Table 2
55Fe uptake by synaptosome preparations challenged by drugs related to intracellular calmodulin signaling
Addition Percentage of uptake
None 100 þ 2
CPZ 250 WM 165 þ 12
CaM 10 WM 500 þ 18
Forskolin 10 WM 102 þ 4
Isoprenaline 10 WM 104 þ 2
Okadaic acid 1 WM 107 þ 3
Staurosporine 5 WM 82 þ 3
CPZ 250 WM+staurosporine 5 WM 152 þ 4
Vanadate 100 WM 75 þ 3
Synaptosome preparations (0.5 mg/ml) were resuspended in 10 mM HEPES bu¡er, pH 7.4, containing 124 mM NaCl, 5 mM KCl,
1.24 mM KH2PO4, 1.3 mM MgCl2, 1 mM CaCl2 and 10 mM glucose, and incubated at 37‡C for 20 min after addition of indicated
drugs and of 50 WM 55Fe-citrate. When vanadate was used, samples were pre-incubated for 10 min before 55Fe-citrate addition. 55Fe
uptake was determined as described in Section 2. Results are means þ S.D. of two independent assays performed in triplicate.
Fig. 2. Synaptosomal iron uptake from 55Fe-transferrin in the
presence of neuroleptic drugs. Conditions of the assay were the
same as described in Fig. 1. Samples were incubated at 37‡C
for 30 min, in the presence of indicated neuroleptic concentra-
tions and 50 WM 55Fe-transferrin. After incubation, samples
were washed twice by centrifugation and iron uptake deter-
mined as described in Section 2. CaM, 10 WM calmidazolium.
Control, drug-free samples. Results represent data of three to
four independent experiments which agreed within 10%.
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greatly dependent on intracellular free Ca2 and, as
veri¢ed previously [8], extracellular Ca2 is needed
for iron uptake, 55Fe-citrate was assayed in the pres-
ence of nifedipine, a speci¢c Ca2 voltage-dependent
channel blocker, FURA2-AM-loaded synaptosomes
in order to chelate intrasynaptosomal free Ca2 (10^
100 nM) [19,20], and 50 mM KCl to mimic mem-
brane depolarization allowing Ca2 in£ux from the
1 mM calcium-containing medium. These results are
listed in Table 3 which shows that 10 and 50 WM
Table 3
E¡ect of Ca2 on 55Fe uptake by synaptosome preparations
Addition Percentage of uptake
1 mM Ca2
None 100 þ 2
CPZ 250 WM 163 þ 15
NF 10 144 þ 4
NF 50 161 þ 7
CPZ 250 WM+NF 10 158 þ 15
CPZ 250 WM+NF 50 195 þ 16
FURA2-AM 3 WM 90 þ 4
CPZ 250 WM+FURA2-AM 3 WM 156 þ 7
KCl 50 mM 50 þ 2
CPZ 250 WM+KCl 50 mM 80 þ 3
Ca2-free
None 3.1 þ 0.5
CPZ 250 WM 58 þ 3
When FURA2-AM was used, synaptosome preparations were
¢rst treated with 3 WM FURA2-AM, as follows: incubation for
10 min at 37‡C and twice washed by centrifugation in order to
eliminate extracellular FURA2-AM. Afterwards, samples were
incubated for iron uptake in the same conditions as described
in Table 2, except that 1 mM CaCl2 was absent from the bu¡er
and, when indicated, 1 mM Ca2 was added immediately before
55Fe-citrate addition. Results are means þ S.D. of two independ-
ent assays performed in triplicate.
Table 4
KCl e¡ect upon 55Fe-citrate loaded synaptosome
Incubation time (min) No addition KCl 50 mM
0 100 þ 2 111 þ 5
15 100 þ 3 89 þ 3
30 105 þ 4 95.5 þ 3
Synaptosomes were incubated in the presence of 50 WM 55Fe-
citrate for 30 min at the same conditions as described in Table
2. Afterwards, samples were washed twice by centrifugation to
remove extracellular iron and incubated at the indicated condi-
tions and times for iron determination. Results are means þ
S.D. of two independent assays performed in triplicate.
Fig. 3. Synaptosomal iron uptake from 55Fe-citrate at increasing vanadate concentrations. Conditions of the assay were the same as
described in Fig. 1. Samples were pre-incubated at 37‡C for 10 min, in the presence of indicated VO33 concentrations before addition
of 50 WM 55Fe-citrate. After incubation for 20 min in the presence of 55Fe-citrate, the samples were washed twice by centrifugation
and iron uptake determined as described in Section 2. Inset: synaptosome preparation incubated as described above, in the presence
of 250 WM CPZ. Results represent data of three to four independent experiments which agreed within 10%.
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nifedipine increases iron uptake in both CPZ-incu-
bated and control samples. Fifty micromolar nifedi-
pine increased 55Fe uptake from control samples by
61% and from CPZ-incubated samples by 20%.
FURA2-AM showed a slightly inhibitory e¡ect
upon control samples (10%) and no e¡ect on CPZ-
treated samples. In contrast, iron uptake was highly
inhibited by 50 mM KCl (50%). When CPZ-treated
samples were incubated in the presence of 50 mM
KCl at increasing CPZ concentrations (Fig. 4), 55Fe
uptake was reduced by 50% in all concentrations of
CPZ tested, compared to samples incubated with
5 mM KCl. In an attempt to verify whether the
depolarization e¡ect could be due to release of iron
taken up during the time of incubation, synaptosome
preparations were loaded with 50 WM 55Fe-citrate,
washed by centrifugation and then incubated with
250 WM CPZ and the internalized 55Fe determined
at increasing times. As can be seen in Table 4, 55Fe
was not released from synaptosomes incubated or
not with 50 mM KCl. Results shown refer to the
e¡ect of KCl on iron uptake from 55Fe-citrate, but
similar results were obtained with 55Fe-Tf as iron
donor (not shown).
As veri¢ed previously [8], and here reproduced,
iron uptake from 55Fe-citrate in the absence of ex-
tracellular Ca2 (synaptosomes were resuspended in
Ca2-free bu¡er) was almost completely inhibited
and in CPZ-incubated samples 55Fe uptake was re-
duced with approx. 38% when compared to CPZ-in-
cubated samples in the presence of added Ca2 (Ta-
ble 2) but still 25% higher than in control samples.
This result suggests that extracellular Ca2 has an
important role on iron uptake but the CPZ-induced
iron uptake is not totally dependent on extracellular
Ca2.
That iron uptake from 55Fe-citrate and stimulated
uptake by neuroleptic drugs were not linked to ionic
pump activity was veri¢ed by incubation of synapto-
some preparations in the presence of ATP (not
shown). In this condition no alteration of 55Fe up-
take was veri¢ed.
4. Discussion
Data presented here suggest that iron uptake from
55Fe-citrate and 55Fe-transferrin by synaptosome
preparation is stimulated by phenothiazine neurolep-
tic drugs other than CPZ (Figs. 1 and 2). Notewor-
thy in this respect is that phenothiazine compounds
are the most potent calmodulin antagonists ([15,16];
Table 1). Furthermore, iron uptake was shown to be
dependent on protein phosphorylation since pre-in-
cubation of synaptosome preparations with vanadate
greatly inhibited iron uptake from 55Fe-citrate (Fig.
3), and to be dependent on membrane polarization
since membrane depolarization by 50 mM KCl
highly inhibited iron uptake from 55Fe-citrate (Fig.
4).
Nevertheless the tests used to link iron uptake
stimulation by CPZ with its calmodulin antagonistic
property (Table 2) failed to show that intrasynapto-
somal-dependent calmodulin signaling can be in-
volved in iron uptake by 55Fe-citrate.
The role of Ca2 on the iron uptake studied here
can be summarized as follows. Membrane depolari-
zation promoted by 50 mM KCl, when Ca2 in£ux is
greatly intensi¢ed, highly inhibited iron uptake (Ta-
ble 3 and Fig. 4), both in control and CPZ-treated
samples. Nifedipine, a Ca2 voltage-dependent chan-
nel blocker, stimulated iron uptake by control sam-
Fig. 4. E¡ect of synaptosomal membrane depolarization on
55Fe uptake. Conditions of the assay were the same as de-
scribed in Fig. 1. Samples were incubated at 37‡C for 20 min,
in the presence of indicated CPZ concentrations and 50 WM
55Fe-citrate. KCl was aliquoted immediately before 55Fe-citrate
addition. After incubation, samples were washed twice by cen-
trifugation and iron uptake determined as described in Section
2. Results represent the means þ S.D. of three independent ex-
periments.
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ples and had little e¡ect upon CPZ-incubated sam-
ples. Chelation of intrasynaptosomal free Ca2 by
FURA2-AM had no apparent e¡ect. Iron uptake
by synaptosome preparations incubated in Ca2-
free medium dramatically decreased in control sam-
ples but had little e¡ect upon CPZ-incubated sam-
ples. Altogether, these results suggest that iron up-
take from 55Fe-citrate is greatly in£uenced by
extracellular Ca2 and does not respond to intrasy-
naptosomal free Ca2 levels. On the other hand,
CPZ-stimulated 55Fe uptake was slightly in£uenced
by extracellular Ca2 variations and not in£uenced
by intrasynaptosomal free Ca2 chelation. Neverthe-
less, membrane depolarization by 50 mM KCl sig-
ni¢cantly decreased 55Fe uptake by CPZ-treated syn-
aptosome preparations (Fig. 4).
The observed vanadate inhibitory e¡ect upon iron
uptake (Fig. 3) could be related to the activity of a
speci¢c phosphorylated protein essential for iron up-
take or for the maintenance of membrane polariza-
tion whose charge distribution on its surface would
favor membrane interaction with iron complexes.
Our data on the e¡ect of phenothiazine drugs
upon iron uptake from 55Fe-citrate and 55Fe-Tf by
synaptosome preparations indicate that the stimula-
tory e¡ect observed and lack of or decreased respon-
siveness by CPZ-incubated preparations challenged
at conditions that altered iron uptake by control
samples, may result from membrane physical alter-
ations causing increased permeability associated with
the destabilization of ion pumps. That this e¡ect is
related to the calmodulin antagonism property of
these drugs could not yet be clearly evidenced. In
this respect, the only information favoring this hy-
pothesis is the stimulatory e¡ect promoted by calm-
idazolium and the e¡ect on iron uptake by neuro-
leptic drugs paralleling the parameter of calmodulin
inhibition (Table 1) and the inhibitory e¡ect pro-
moted by membrane depolarization (Fig. 4), which
promotes Ca2 in£ux and activation of calmodulin.
That calmodulin has an important role in synaptic
terminals in both pre- and postsynaptic portions and
that neurons of some brain areas are enriched in
calmodulin can be drawn from the literature
[17,18]. Inasmuch as the property shared by these
drugs is calmodulin antagonism, and if this deter-
mines iron uptake stimulation, then it can be inferred
that all other neuroleptic drugs have inherent poten-
tial to stimulate iron uptake by neuronal synaptic
terminals.
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